June 21, 2017
The FDA recently approved Mydayis, a once-daily mixed salts of a single-entity amphetamine product from Shire, for treatment of ADHD in individuals aged 13 years and older.
"The approval of Mydayis provides clinicians with another option to treat their patients with ADHD ages 13 and older," study researcher Andrew J. Cutler, MD, executive vice president and chief medical officer at Meridien, told Healio/Psychiatry. "In particular, there is a need for more approved medications for adults with ADHD. Adults have long days, which require control of symptoms in several settings, such as home, school or work, and socially. In clinical trials in adults with ADHD, Mydayis was shown to treat symptoms of ADHD for up to 16 hours. Mydayis therefore provides clinicians with a new once a day treatment that can be effective for their appropriate patients with ADHD ages 13 and older."